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Anticholinergic drugs have long played an important role in the man-
agement of bladder symptoms, which reduce incontinence and ur-
gency1 while improving quality of life. However, these benefits need 
to be considered in relation to potential adverse effects. In particular, 
there is now a need to review the evidence for anticholinergics as a risk 
factor for the development of dementia. This article focuses on anti-
cholinergics used for bladder symptoms as these are commonly used, 
particularly in the elderly, and alternative treatments are available.
Several anticholinergic drugs are licensed for treatment of blad-
der conditions, including selective antimuscarinic drugs that only 
affect the bladder, such as solifenacin and darifenacin, and nonse-
lective antimuscarinics that affect receptors in both the bladder and 
the brain, such as oxybutynin. Other bladder treatments without 
anticholinergic properties include the newer drug mirabegron and 
non- drug interventions. The trends in defined daily doses (DDDs) of 
anticholinergics and mirabegron using data from the NHS Business 
Services Authority on medications dispensed in the community in 
England between 2010 and 2019 are shown in Figure 1.
In 2019, over 187 million DDDs of these anticholinergics were 
dispensed, an increase of 61% since 2010. During this period, DDDs 
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Abstract
Evidence suggests that the prescription of bladder anticholinergics is increasing. 
Recent studies have accentuated concerns about whether certain prescribed medica-
tions could increase risk of dementia, including anticholinergic drugs, and specifically 
anticholinergics used for bladder symptoms. Nevertheless, it can be difficult to draw 
together the evidence to review the case for possible causation. Recognising this issue 
in 1965, Bradford- Hill set out nine criteria to help assess whether evidence of a causal 
relationship could be inferred between a presumed cause and an observed effect. 
In this commentary, we explore the extent to which associations between anticho-
linergics and dementia satisfy the Bradford- Hill criteria and examine the potential 
implications. First, we look at studies that have examined the relationship between 
anticholinergic drugs with urological properties (bladder drugs) and the onset of de-
mentia, and then present those studies which specifically focus on the cognitive ef-
fects of bladder drugs that affect muscarinic receptors in the brain versus the bladder 
on older people along with suggestions for future research. We also discuss the risks 
and benefits of these drugs for treating overactive bladder. If it can be shown that 
certain medications carry a specific risk of dementia, it is possible that initiatives to 
change prescribing could become a key tool in reducing the risk of dementia and may 
be easier to implement than some lifestyle changes.
K E Y W O R D S
anticholinergics, bladder symptoms, Bradford- Hill criteria, dementia, deprescribing
2 of 4  |     COMMENTARY
dispensed for solifenacin more than doubled to 106 million in 2019, 
while DDDs dispensed for oxybutynin increased by 16% to 22 mil-
lion in 2019, and 36 million DDDs were dispensed for mirabegron in 
2019. Given the substantial and increasing prescription of bladder 
treatment anticholinergics, it is important to have more clarity re-
garding risks of dementia. To explore a potential causative link be-
tween bladder anticholinergics and dementia, we have assessed the 
evidence using the Bradford Hill2 criteria, which are listed in Box 1.
Turning to the literature, a growing number of studies, including 
those by Richardson3 and Coupland4 have found a strong longitudi-
nal association between anticholinergic drugs with urological prop-
erties and dementia risk over various time intervals between taking 
the anticholinergic and the development of dementia. Importantly, 
both studies accounted for protopathic biases by excluding prescrip-
tions in periods close to the diagnosis of dementia. Furthermore, in 
Coupland's4 study, the adjusted odds ratios for dementia diagnosis 
increased with higher cumulative dosages of bladder antimuscarin-
ics, which means that (1) strength of association, (4) temporality, 
and a (5) biological gradient or dose– response relationship were 
demonstrated.
Randomized controlled trials (RCTs) investigating anticholin-
ergic drugs with different effects on muscarinic receptors in the 
brain versus the bladder found that cognitive functions were not 
compromised by darifenacin (a selective antimuscarinic) but were 
negatively affected by oxybutynin (a nonselective antimuscarinic).5 
Furthermore, higher doses of oxybutynin were associated with 
greater memory problems.5 Trospium5 and solifenacin6 (bladder- 
selective antimuscarinics) were also not associated with cognitive 
impairment, including higher dosages of solifenacin.6 Most of these 
studies involved participants aged 60 years and older. Using the 
Bradford Hill2 criteria, these RCTs appear to show (2) consistency, 
(3) specificity, in that cognitive functions were not compromised by 
selective antimuscarinics that affect only the bladder, a (5) dose– 
response relationship, and (8) experimental evidence. It should be 
noted, however, that while the trials involving darifenacin, solifena-
cin, and trospium are reassuring,5,6 the studies were of short dura-
tion and assessed cognitive function rather than the development 
of dementia.
The criteria of plausibility (6), in which the association can be 
accommodated within existing biological models and coherence 
(7), which means that the data should not conflict with known bi-
ological facts, are supported by the fact that oxybutynin is a small 
molecule relative to selective antimuscarinics, which increases the 
ability of this drug to cross the blood– brain barrier. In contrast, 
trospium, due to its quaternary structure, is much less likely to 
cross the blood– brain barrier.7 Furthermore, efflux transporters 
F I G U R E  1 Defined	daily	doses	by	
year of various bladder treatment drugs 
(2010– 2019).















BOX 1 Bradford Hill2 criteria
1) Strength of association, in which the larger the association, the more likely a causal relationship can be inferred.
2) Consistency, or repetitiveness in the findings, where a variety of locations, methods, and populations show the same results.
3) Specificity, in which one exposure causes only one disease.
4) Temporality, in which exposure precedes the disease in time, which can include low exposure over long time periods.
5) Biological gradient, where there is a dose– response relationship between the exposure and the effect.
6) Plausibility, in which the association can be accommodated within existing biological or social models.
7) Coherence, where the cause and effect relationship is bolstered by all of the evidence available to the researcher.
8) Experiment, in which an intervention reduces exposure, thereby reducing the risk of the disease.
9) Analogy, which allows the researcher to accept weaker evidence for a relationship if a stronger causal relationship has been established 
between a similar agent and a similar disease.
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pump darifenacin and trospium from the blood vessels of the 
cerebral cortex, but no such mechanism has been identified for 
oxybutynin.8 Pagoria8 noted that the blood– brain barrier may be 
compromised in older people, which may further increase the risk. 
More generally, anticholinergics may alter the brain resulting in 
atrophy and reduced glucose metabolism.9 Risacher10 found that 
those who used anticholinergics not only showed cognitive de-
cline on memory tests, but also greater brain atrophy as measured 
by structural magnetic resonance imaging (MRI) and lower levels 
of glucose metabolism as measured by positron emission tomogra-
phy. This supports the premise that the use of anticholinergics al-
ters the cholinergic connections responsible for cognition in older 
adults. Finally, Perry11 reported that long- term use of antimus-
carinics, in contrast to short- term use, was associated with more 
neurofibrillary tangles and amyloid plaques, and concluded that 
the blockade of M1 receptors may be responsible for this effect. 
This supports the Bradford Hill2 criteria of analogy (9) because 
plaques and tangles are strongly associated with Alzheimer's 
disease, and the use of antimuscarinics is associated with more 
plaques and tangles; therefore, antimuscarinics may increase the 
risk of Alzheimer's disease. It should be noted that only antimus-
carinics that block M1 receptors appear to produce this effect, so 
bladder drugs, such as darifenacin and solifenacin, which selec-
tively block M3 receptors,
12,13 may not be linked to Alzheimer's 
disease.
In summary, it appears that the use of oxybutynin satisfies the 
Bradford Hill criteria for establishing a causal link with the develop-
ment of dementia, and this may also be the case for other anticholin-
ergics that easily cross the blood– brain barrier. Should doctors and 
pharmacists make the case for avoiding anticholinergics associated 
with risk of dementia? The precautionary principle would suggest 
that we should act now and advise colleagues not to use anticholin-
ergics associated with dementia for bladder symptoms when there 
are alternatives that appear to be safer. Anticholinergic burden 
scales, which assess the cumulative effect of taking medicines with 
anticholinergic properties, can be used to help clinicians identify pa-
tients at risk from the adverse effects of anticholinergic drugs that 
are linked to dementia. A key challenge is to flag up at- risk patients 
to clinicians, and this is where GP computer systems can be very 
helpful due to automation of patient records.
There are, of course, other considerations when balancing 
benefits and risks when considering prescribing antimuscarinics 
for bladder symptoms. Antimuscarinic drugs are beneficial in im-
proving the symptoms of overactive bladder, improving quality 
of life, and reducing incontinence, micturition frequency, and ur-
gency episodes.14 However, in addition to the risks of dementia 
associated with oxybutynin, this drug exhibited side effects more 
commonly than solifenacin or trospium, namely, a greater risk of 
dry mouth and withdrawals due to adverse effects.15 Furthermore, 
although higher doses of oxybutynin and solifenacin were better 
at controlling bladder symptoms, this was associated with more 
withdrawals due to adverse effects for oxybutynin and more in-
stances of dry mouth for solifenacin.15 Mirabegron is a newer drug 
for controlling bladder symptoms that is not an anticholinergic and 
is not thought to be associated with dementia; it appears to have 
fewer side effects than solifenacin but may be less effective in 
controlling symptoms.16,17
Campbell18 suggests that future research should implement 
a deprescribing intervention as the next step, to not only investi-
gate whether reducing anticholinergic use improves cholinergic 
transmission and reduces risk of dementia but also to evaluate the 
possible harm that comes from deprescribing these drugs. Further 
research could look at whether substituting selective antimuscarin-
ics or other drugs, such as mirabegron, for nonselective ones im-
proves memory function and delays the onset of dementia in older 
adults. Of course, as Campbell18 notes, if deprescribing comes too 
late in the disease process, then an improvement in cognition may 
not be detected, so selecting the appropriate population becomes 
critical in order to maximize the potential of detecting a clinically 
meaningful change in cognition. The interaction of dementia drugs 
(acetylcholinesterase inhibitors) and bladder drugs (anticholiner-
gics) also needs to be investigated further as use of anticholinergics 
may reduce the efficacy of drugs prescribed for treating demen-
tia. If it can be established that certain medications carry a specific 
increased risk of dementia, it is possible that initiatives to change 
prescribing could become a key tool in reducing the risk of dementia 
and may be easier to implement than some lifestyle changes.
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